Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Lenvima: advanced Endometrial Carcinoma with MSI-H stated without a specific alteration after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.4 Endometrial Carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration ( 2.1 )] .

Broader topic: Endometrial Cancer

Source population
Not part of this definition
Disease extent
advanced
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    MSI-H
    alteration
    stated without a specific alteration
    status
    present
prior therapy
  1. class
    following prior systemic therapy in any setting and are not candidates for curative surgery or ra
    status
    required
derivation status
source-attested
derivation note
Scoped from the FDA approved indication for Lenvima (product label). Only dimensions stated in that wording are part of this definition.
source wording
1.4 Endometrial Carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation [see Dosage and Administration ( 2.1 )] .

Study evidence for this setting

1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

NCT05714553 · Registry condition search · Scope: unclear

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

3 outcome links · 2 safety-group records · 0 quality-of-life measures

→
Source relationships and population-mapping limitations
bindings
    mappings

      Download this complete draft source relationship record →

      Preserved source evidence · Not medical advice